CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 19532

APPROVABLE LETTER

JUL 30 1987

Pennwalt Corporation
Pharmaceutical Division
Attention: Keith S. Rotenberg, Ph.D.
Post Office Box 1710
Rochester, NY 14603

Dear Dr. Rotenberg:

Please refer to your October 4, 1985 new drug application submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for Microx® (metolazone) 1/2 mg Tablets.

We also acknowledge receipt of your amendments dated November 19, 1985; January 2, February 12 (two), May 15 (two), June 19 and 27 (two), July 15, August 8, September 3, 12 and 26, October 31 and December 2, 1986; March 27, and May 29, 1987; and your correspondence dated March 6, 1987.

We have completed the review of this application as submitted with draft labeling. Before the application may be approved, however, it will be necessary for you to submit final printed labeling for the drug. The labeling should be essentially identical in content to the enclosed marked-up draft. In addition, please add to container labels and other labels the statement: DO NOT INTERCHANGE; formulations equivalent to Microx and formulations equivalent to Zaroxolyn should not be interchanged (see package insert). If additional information relating to the safety or effectiveness of this drug becomes available before we receive the final printed labeling, revision of that labeling may be required.

The Division of Biopharmaceutics requests that you submit dissolution data for a lot of Microx 1/2 mg tablets using a 50 rpm stirring speed. The dissolution conditions and Q specification of the tablets will be established upon the review of the 50 rpm dissolution data. Please send the Microx 1/2 mg tablets (3 X 100) to:

Acting Branch Chief
Biopharmaceutics Laboratory Branch (HFN-224)
FOB-8
200 C Street, S.W.
Washington, D.C. 20204

In addition, we would appreciate your submitting copies of the introductory promotional material that you propose to use for this product. Please submit

one copy to this Division and a second, along with a copy of the package insert, directly to:

Division of Drug Advertising and Labeling, HFN-240
Room 10B-04
5600 Fishers Lane
Rockville, Maryland 20857

Please submit all proposed materials in draft or mock-up form, not final print. Also, please do not use form FD-2253 for this submission; this form is for routine use, not proposed materials.

Please submit twelve copies of the printed labels and other labeling seven of which are individually mounted on heavy weight paper or similar material.

Within 10 days after the date of this letter, you are required to amend the application, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of such action FDA may take action to withdraw the application.

The drug may not be legally marketed until you have been notified in writing that the application is approved.

Should you have any questions, please contact:

Mr. Warren Rumble
Consumer Safety Officer
Telephone: (301) 443-4730

Sincerely yours,

Robert Temple, M.D.
Director
Office of Drug Research and Review
Center for Drugs and Biologics

Enclosures